drugset / Trial / NCT00866437

Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel

NCT00866437

Phase 2 Unknown 40 enrolled EVE Medical Systems Ltd.
RandomizedFactorialSingle-blindDiagnostic

Summary

The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS). The system includes skin testing panel for identification of hormones to which the patients might be sensitive. Tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests and patient's history will determine the value of EVE-PMS Skin-Test Panel as a diagnostic tool for severe PMS patients.

Timeline

Start
2009-04
Primary completion
2010-05
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 1 mmol
Subject Estriol Unknown 3 mmol
Subject Estrone Small molecule 3 mmol
Subject Progesterone Other / unclassified 1 mmol
Background Histamine Small molecule 1 mg/ml Other

Indications